About
We aim to address a major problem in anticancer drug delivery where less than 1% of injected drugs can penetrate a disease owing to biological barriers such as the blood-brain barrier or the tumor-endothelium leading to poor prognosis, survival outcomes and terrible side effects such as weight loss, hair loss and vomiting. Our solution involves the use of ultrasound triggered microbubbles proven safe for diagnostic imaging, which have been optimized to solve cancer drug delivery. Our innovation is the development of stable large monodisperse size-isolated microbubbles (SIMBs), which have been validated in preclinical studies to
We aim to address a major problem in anticancer drug delivery where less than 1% of injected drugs can penetrate a disease owing to biological barriers such as the blood-brain barrier or the tumor-endothelium leading to poor prognosis, survival outcomes and terrible side effects such as weight loss, hair loss and vomiting. Our solution involves the use of ultrasound triggered microbubbles proven safe for diagnostic imaging, which have been optimized to solve cancer drug delivery. Our innovation is the development of stable large monodisperse size-isolated microbubbles (SIMBs), which have been validated in preclinical studies to
- Enable safe, transient and noninvasive opening of the blood-brain barrier for drug delivery.
- Improve the efficacy and survival benefit of an immunotherapy for Pancreatic cancer treatment.
- Enable treatment of high-risk Neuroblastoma with liposomal doxorubicin (L-Dox) while eliminating its chemo-toxic drug side effects.
